Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000000201 | SCV000361347 | pathogenic | Ornithine aminotransferase deficiency | 2024-11-22 | criteria provided, single submitter | clinical testing | The OAT c.192_193delAG (p.Gly65LysfsTer15) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant is not observed at a significant frequency in version 4.1.0 of the Genome Aggregation Database. The p.Gly65LysfsTer15 variant was identified in trans with a pathogenic variant in at least one individual with a phenotype consistent with ornithine aminotransferase deficiency (PMID:1609808). Functional studies conducted in patient fibroblasts demonstrated that this variant impacts protein function (PMID:1609808). Based on the available evidence, the c.192_193delAG (p.Gly65LysfsTer15) variant is classified as pathogenic for ornithine aminotransferase deficiency. |
Labcorp Genetics |
RCV000000201 | SCV001588482 | pathogenic | Ornithine aminotransferase deficiency | 2024-01-02 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly65Lysfs*15) in the OAT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OAT are known to be pathogenic (PMID: 1737786, 23076989). This variant is present in population databases (rs386833600, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with clinical features of gyrate atrophy (PMID: 1609808). This variant is also known as 2-bp deletion (AG). ClinVar contains an entry for this variant (Variation ID: 178). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000000201 | SCV004208942 | pathogenic | Ornithine aminotransferase deficiency | 2024-02-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000000201 | SCV005668010 | likely pathogenic | Ornithine aminotransferase deficiency | 2024-06-10 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000000201 | SCV000020344 | pathogenic | Ornithine aminotransferase deficiency | 1992-07-01 | no assertion criteria provided | literature only | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000000201 | SCV000081964 | probable-pathogenic | Ornithine aminotransferase deficiency | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000000201 | SCV002095282 | pathogenic | Ornithine aminotransferase deficiency | 2021-06-01 | no assertion criteria provided | clinical testing |